Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
Domain	FERM_central	JAK2 KRIT1	3.18e-03	49	32	2	IPR019748
Domain	FERM_domain	JAK2 KRIT1	3.18e-03	49	32	2	IPR000299
Domain	FERM_1	JAK2 KRIT1	3.31e-03	50	32	2	PS00660
Domain	FERM_2	JAK2 KRIT1	3.31e-03	50	32	2	PS00661
Domain	Band_41_domain	JAK2 KRIT1	3.31e-03	50	32	2	IPR019749
Domain	B41	JAK2 KRIT1	3.31e-03	50	32	2	SM00295
Domain	FERM_3	JAK2 KRIT1	3.31e-03	50	32	2	PS50057
Domain	-	LAMA2 PCSK4	6.93e-03	73	32	2	2.60.120.260
Domain	Galactose-bd-like	LAMA2 PCSK4	1.13e-02	94	32	2	IPR008979
Pubmed	The protein tyrosine phosphatase-PEST is implicated in the negative regulation of epidermal growth factor on PRL signaling in mammary epithelial cells.	JAK2 PTPN12	8.20e-07	2	32	2	11731619
Pubmed	Integrin β6 can be translationally regulated by eukaryotic initiation factor 4E: Contributing to colonic tumor malignancy.	ITGAV EIF4E	2.46e-06	3	32	2	25982998
Pubmed	Nuclear eIF4E Stimulates 3'-End Cleavage of Target RNAs.	CPSF3 EIF4E	2.46e-06	3	32	2	31042468
Pubmed	Phosphatidylinositol 3,4,5-trisphosphate directs association of Src homology 2-containing signaling proteins with gelsolin.	PTPN12 ITGAV	4.49e-05	11	32	2	11577104
Pubmed	Integrin repertoire on myogenic cells changes during the course of primary myogenesis in the mouse.	LAMA2 ITGAV	4.49e-05	11	32	2	15739233
Pubmed	Characterizing WW domain interactions of tumor suppressor WWOX reveals its association with multiprotein networks.	KDM3B PDCD7 CPSF3 DCAF7	4.88e-05	220	32	4	24550385
Pubmed	An E3 ubiquitin ligase, Really Interesting New Gene (RING) Finger 41, is a candidate gene for anxiety-like behavior and beta-carboline-induced seizures.	KDM3B OGFOD1	6.36e-05	13	32	2	18986647
Pubmed	Talin 1 and 2 are required for myoblast fusion, sarcomere assembly and the maintenance of myotendinous junctions.	LAMA2 ITGAV	8.55e-05	15	32	2	19793892
Pubmed	Functional proteomics mapping of a human signaling pathway.	KDM3B PTPN12 KMT2B PDCD7 TBCD	1.92e-04	591	32	5	15231748
Pubmed	Tsg101 Is Necessary for the Establishment and Maintenance of Mouse Retinal Pigment Epithelial Cell Polarity.	TSG101 ITGAV	2.43e-04	25	32	2	33795534
Pubmed	A Y2H-seq approach defines the human protein methyltransferase interactome.	KDM3B MALT1 ZNF165 ANKEF1	2.66e-04	342	32	4	23455924
Pubmed	Solubility-based genetic screen identifies RING finger protein 126 as an E3 ligase for activation-induced cytidine deaminase.	CPSF3 FEN1	4.00e-04	32	32	2	23277564
Pubmed	Exome sequencing supports a de novo mutational paradigm for schizophrenia.	LAMA2 SLC26A7	6.26e-04	40	32	2	21822266
Pubmed	FBXL13 directs the proteolysis of CEP192 to regulate centrosome homeostasis and cell migration.	NEB SACS	6.90e-04	42	32	2	29348145
Pubmed	Single-cell profiling of epigenetic modifiers identifies PRDM14 as an inducer of cell fate in the mammalian embryo.	KDM3B KMT2B	7.57e-04	44	32	2	24183668
Pubmed	Large-scale structural analysis of the classical human protein tyrosine phosphatome.	JAK2 PTPN12	8.64e-04	47	32	2	19167335
GeneFamily	Ankyrin repeat domain containing\|FERM domain containing	JAK2 KRIT1	1.83e-03	50	23	2	1293
ToppCell	Brain_organoid-organoid_Tanaka_cellReport-5w-Mesenchymal-Cilia-bearing_cell\|5w / Sample Type, Dataset, Time_group, and Cell type.	C17orf67 KMT2B ITGAV ZNF165	6.98e-06	173	32	4	d4cbeae262abfa30d8c5452285d3261a96875610
Drug	Digitoxigenin [143-62-4]; Down 200; 10.6uM; MCF7; HT_HG-U133A	JAK2 ZNF165 SYNJ2 ANKEF1 KRIT1	5.08e-06	181	32	5	3275_DN
Drug	Amitryptiline hydrochloride [549-18-8]; Down 200; 12.8uM; HL60; HT_HG-U133A	KDM3B JAK2 PTPN12 SYNJ2 MAGEF1	6.12e-06	188	32	5	1865_DN
Drug	geldanamycin; Down 200; 1uM; MCF7; HT_HG-U133A_EA	KMT2B SYNJ2 ANKEF1 TBCD KRIT1	6.60e-06	191	32	5	1008_DN
Drug	Nystatine [1400-61-9]; Down 200; 4.4uM; MCF7; HT_HG-U133A	JAK2 PTPN12 NEB SACS MAGEF1	8.26e-06	200	32	5	4807_DN
Drug	picumast	PDP1 KRIT1	6.85e-05	9	32	2	CID000431850
Drug	ICI 182,780; Down 200; 1uM; MCF7; HT_HG-U133A	JAK2 PTPN12 SACS TBCD	1.14e-04	180	32	4	5202_DN
Drug	5224221; Down 200; 12uM; MCF7; HT_HG-U133A_EA	JAK2 SYNJ2 MAGEF1 FEN1	1.14e-04	180	32	4	956_DN
Drug	Lanatoside C [17575-22-3]; Down 200; 4uM; MCF7; HT_HG-U133A	JAK2 SACS SYNJ2 ANKEF1	1.17e-04	181	32	4	6048_DN
Drug	Digoxin [20830-75-5]; Down 200; 5.2uM; MCF7; HT_HG-U133A	JAK2 SACS ANKEF1 KRIT1	1.19e-04	182	32	4	5324_DN
Drug	Lanatoside C [17575-22-3]; Down 200; 4uM; MCF7; HT_HG-U133A	JAK2 SACS TBCD KRIT1	1.22e-04	183	32	4	3963_DN
Drug	Helveticoside [630-64-8]; Down 200; 7.4uM; MCF7; HT_HG-U133A	JAK2 SACS ANKEF1 KRIT1	1.24e-04	184	32	4	3945_DN
Drug	Lanatoside C [17575-22-3]; Down 200; 4uM; MCF7; HT_HG-U133A	JAK2 SACS ANKEF1 KRIT1	1.24e-04	184	32	4	3852_DN
Drug	N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide	JAK2 EIF4E	1.25e-04	12	32	2	ctd:C546012
Drug	Fenbufen [36330-85-5]; Down 200; 15.8uM; PC3; HT_HG-U133A	JAK2 PTPN12 NEB PDP1	1.44e-04	191	32	4	4279_DN
Drug	Bisacodyl [603-50-9]; Down 200; 11uM; PC3; HT_HG-U133A	PTPN12 KMT2B SYNJ2 KRIT1	1.49e-04	193	32	4	4616_DN
Drug	Flumethasone [2135-17-3]; Down 200; 9.8uM; PC3; HT_HG-U133A	JAK2 SYNJ2 PDP1 KRIT1	1.52e-04	194	32	4	4272_DN
Drug	Clofazimine [2030-63-9]; Up 200; 8.4uM; PC3; HT_HG-U133A	LAMA2 JAK2 NEB ZNF165	1.55e-04	195	32	4	4682_UP
Drug	Azapropazone [13539-59-8]; Down 200; 13.4uM; MCF7; HT_HG-U133A	JAK2 NEB SYNJ2 MAGEF1	1.55e-04	195	32	4	6522_DN
Drug	Mefenamic acid [61-68-7]; Up 200; 16.6uM; PC3; HT_HG-U133A	JAK2 KMT2B SYNJ2 MAGEF1	1.59e-04	196	32	4	1821_UP
Drug	rosiglitazone; Down 200; 10uM; MCF7; HT_HG-U133A	MALT1 PTPN12 TBCD DCAF7	1.59e-04	196	32	4	5593_DN
Drug	2-propylpentanoic acid; Down 200; 1000uM; MCF7; HT_HG-U133A	MALT1 KMT2B SYNJ2 PDP1	1.59e-04	196	32	4	5569_DN
Drug	Carbimazole [22232-54-8]; Down 200; 21.4uM; HL60; HT_HG-U133A	JAK2 KMT2B SYNJ2 MAGEF1	1.59e-04	196	32	4	2437_DN
Drug	Metergoline [17692-51-2]; Down 200; 10uM; MCF7; HT_HG-U133A	MALT1 PTPN12 SACS KRIT1	1.62e-04	197	32	4	5344_DN
Drug	Tiaprofenic acid [33005-95-7]; Down 200; 15.4uM; PC3; HT_HG-U133A	JAK2 NEB SYNJ2 MAGEF1	1.62e-04	197	32	4	4091_DN
Drug	Hydroflumethiazide [135-09-1]; Up 200; 12uM; PC3; HT_HG-U133A	KMT2B ZNF165 TBCD KRIT1	1.62e-04	197	32	4	7259_UP
Drug	Diprophylline [479-18-5]; Down 200; 15.8uM; HL60; HT_HG-U133A	JAK2 NEB SYNJ2 KRIT1	1.65e-04	198	32	4	1853_DN
Drug	Adiphenine hydrochloride [50-42-0]; Down 200; 11.4uM; HL60; HT_HG-U133A	NEB SYNJ2 MAGEF1 TBCD	1.71e-04	200	32	4	1872_DN
Drug	Ser-Leu	SACS PDP1	1.99e-04	15	32	2	CID006427005
Disease	breast cancer (is_marker_for)	KDM3B TSG101 KMT2B FEN1	4.12e-05	185	31	4	DOID:1612 (is_marker_for)
Disease	retinal detachment, retinal break	LAMA2 C17orf67	6.22e-04	35	31	2	EFO_0005773, EFO_0010698
Disease	colorectal adenocarcinoma (is_implicated_in)	KMT2B PCSK4	6.22e-04	35	31	2	DOID:0050861 (is_implicated_in)
Disease	Diffuse Large B-Cell Lymphoma	JAK2 MALT1	1.53e-03	55	31	2	C0079744
Disease	response to alcohol	LAMA2 CNGB1	2.83e-03	75	31	2	EFO_0005526

Protein segments in the cluster

Peptide	Gene	Start	Entry
LILDEYWQNHPELHD	CPSF3	251	Q9UKF6
PGLHPHEWTYEEQFK	ARID3C	91	A6NKF2
DHPPEHPIQDDSVWY	ANKEF1	471	Q9NU02
YEDPQHHPLLRLCWN	DCAF7	216	P61962
YEDRHQLPAPKWAEL	JAK2	766	O60674
SPHIPQDHEILYDWI	OGFOD1	256	Q8N543
LHKKEPQHWPVQYRE	MAGEF1	261	Q9HAY2
PHYQWFKNELPLTHE	MALT1	256	Q9UDY8
PEHYIKHPLQNRWAL	EIF4E	31	P06730
IEKDHPDLWANYDPL	PCSK4	161	Q6UW60
HDWDQYLVPSDHPKG	PDCD7	446	Q8N8D1
PPDHDPIHDQSWYLD	KDM3B	1641	Q7LBC6
PYHKPLQHVRDWPEI	KRIT1	476	O00522
EDLHLEPFYWKLPEQ	LAMA2	1226	P24043
DGPPDLLLESQWHHY	KMT2B	2371	Q9UMN6
LLPILQWHKHPNDYF	PDP1	186	Q9P0J1
HHPVYQWPEDLLKPD	CMPK2	356	Q5EBM0
NKYPVPENWLHKEAH	FEN1	266	P39748
DHVFLPIPNWEHKEN	ITGAV	781	P06756
EEQFLEHWLNPHCKP	C17orf67	66	Q0P5P2
RLYLKWHPDKNPENH	SACS	4331	Q9NZJ4
YQDPFWNLLHHPKLL	SYNJ2	1411	O15056
WQDNDRYHPKPVLHM	PTPN12	381	Q05209
PYQTPDNIHHWLLMD	CNGB1	681	Q14028
LPYLHEWKHPQSDLL	TSG101	111	Q99816
HPVENIPEIILYWKH	SLC25A25	146	Q6KCM7
HWYHPILRLQEAKPQ	WDR97	1531	A6NE52
LPGDLQAWVHEHYPE	ZNF165	101	P49910
LYDWIPQNDLLGHPK	UGT2A3	351	Q6UWM9
KYQEQPHLLDPHLEW	TBCD	66	Q9BTW9
RLPILDWAPHYNLKE	SLC26A7	31	Q8TE54
DWAPHYNLKENLLPD	SLC26A7	36	Q8TE54
VDYKHPLHEWICLPD	NEB	3351	P20929
YKHPLHEWTCLPDQN	NEB	3596	P20929